Voya Investment Management LLC Purchases 10,048 Shares of Vericel Corporation $VCEL

Voya Investment Management LLC increased its position in shares of Vericel Corporation (NASDAQ:VCEL) by 68.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,664 shares of the biotechnology company’s stock after acquiring an additional 10,048 shares during the quarter. Voya Investment Management LLC’s holdings in Vericel were worth $1,101,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Strs Ohio bought a new position in Vericel during the 1st quarter worth approximately $812,000. Intech Investment Management LLC boosted its stake in Vericel by 51.8% during the 1st quarter. Intech Investment Management LLC now owns 53,533 shares of the biotechnology company’s stock worth $2,389,000 after acquiring an additional 18,274 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Vericel by 9.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock worth $5,490,000 after acquiring an additional 10,191 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Vericel by 13.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 44,333 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Vericel by 6.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock worth $1,403,000 after acquiring an additional 1,847 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on VCEL shares. Stephens reissued an “overweight” rating and set a $67.00 price objective on shares of Vericel in a research note on Monday, June 16th. BTIG Research lowered shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Finally, Canaccord Genuity Group cut their price target on shares of Vericel from $61.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 1st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average price target of $60.40.

Vericel Trading Down 1.9%

NASDAQ VCEL opened at $31.21 on Wednesday. The firm’s fifty day moving average price is $35.54 and its two-hundred day moving average price is $39.96. Vericel Corporation has a 1 year low of $29.93 and a 1 year high of $63.00. The firm has a market capitalization of $1.57 billion, a P/E ratio of 260.11 and a beta of 1.33.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm had revenue of $63.24 million for the quarter, compared to analyst estimates of $64.61 million. During the same period in the prior year, the firm posted ($0.10) earnings per share. The company’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, research analysts anticipate that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.